# Investigation of 1.2% Sodium Hyaluronate for Treatment of Painful Chronic Osteoarthritis of the Knee

> **NCT00988091** · PHASE3 · COMPLETED · sponsor: **Ferring Pharmaceuticals** · enrollment: 596 (actual)

## Conditions studied

- Osteoarthritis of the Knee

## Interventions

- **DEVICE:** 1.2% Sodium Hyaluronate
- **DEVICE:** Buffered Saline

## Key facts

- **NCT ID:** NCT00988091
- **Lead sponsor:** Ferring Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-09
- **Primary completion:** 2010-10
- **Final completion:** 2011-04
- **Target enrollment:** 596 (ACTUAL)
- **Last updated:** 2012-06-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00988091

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00988091, "Investigation of 1.2% Sodium Hyaluronate for Treatment of Painful Chronic Osteoarthritis of the Knee". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00988091. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*